Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C

被引:5
作者
Borroni, G. [1 ]
Cazzaniga, M. [2 ]
Andreoletti, M. [3 ]
Ceriani, R. [4 ]
Guerzoni, P. [5 ]
Omazzi, B. [6 ]
Pich, M. G. L. [4 ]
Prada, A. [6 ]
Spinzi, G. [7 ]
Terreni, N. [7 ]
Salerno, F. [2 ]
机构
[1] ASL Prov Milano 1, Unita Org Alcoldipendenze, I-20013 Abbiategrasso, Italy
[2] Univ Milan, Dipartimento Med Interna, IRCCS Policlin S Donato, Milan, Italy
[3] Osped A Manzoni, Unita Operat Med, Lecce, Italy
[4] IRCCS Ist Clin Humanitas, Unita Operat Med Gen & Epatol, Rozzano, Italy
[5] Osped Varese, Unita Operat Gastroenterol, Varese, Italy
[6] Azienda Osped G Salvini, Unita Operat Gastroenterol, Rho, Italy
[7] Osped Valduce, Unita Operat Gastroenterol, Como, Italy
关键词
age; anaemia; chronic hepatitis C; renal function; ribavirin; treatment; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; VIRUS-INFECTION; COMBINATION THERAPY; GENOTYPE; HEMOLYTIC-ANEMIA; RENAL-FUNCTION; PEGINTERFERON; HCV; DISEASE;
D O I
10.1111/jvh.12015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Elderly patients with chronic hepatitis C have a reduced responsiveness to antiviral therapy with Peg-interferon and ribavirin. The dose reduction or the discontinuation of ribavirin due to the occurrence of anaemia is one of the most important causes for the low sustained viral response observed in older patients. We aimed to evaluate the relationship between baseline renal function and the early onset of ribavirin-associated anaemia in older (60years) patients. Using data from 348 patients with chronic hepatitis C consecutively treated with peg-interferon plus ribavirin, we investigated which factors were associated with the occurrence of anaemia in elderly patients (60years). Ribavirin-induced anaemia occurred in 40.5% of patients. Older patients showed a rate of anaemia significantly higher than younger patients (51.5% vs 36.3%; P=0.009). Consequently, the rate of ribavirin dose reduction or discontinuation due to anaemia was 35.1% in older patients and 23.5% in younger patients (P=0.029). A significantly higher proportion of older patients had a low baseline glomerular filtration rate (GFR) compared with younger patients (56.7% vs 27.1%; P<0.001). At the multivariate regression analysis, low baseline GFR (<70mL/min) was associated with an increased risk of ribavirin-associated anaemia only in the older patients (OR: 3.526; 95% CI: 1.3858.979; P=0.008). In this subset, baseline GFR was significantly correlated with both absolute (r=0.320; P<0.001) and relative (r=0.324; P<0.001) haemoglobin decrease within the first 8weeks of treatment. In patients aged >60years, a low pre-treatment GFR was strongly associated with the risk to develop ribavirin-related anaemia with consequent reduction in ribavirin doses.
引用
收藏
页码:e90 / e95
页数:6
相关论文
共 28 条
[1]   The effect of age on response to therapy with peginterferon α plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr [J].
Antonucci, Giorgio ;
Longo, Maria Antonella ;
Angeletti, Claudio ;
Vairo, Francesco ;
Oliva, Alessandra ;
Comandini, Ubaldo Visco ;
Tocci, Guido ;
Boumis, Evangelo ;
Noto, Pasquale ;
Solmone, Maria Carmela ;
Capobianchi, Maria R. ;
Girardi, Enrico .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (07) :1383-1391
[2]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[3]   Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency [J].
Bruchfeld, A ;
Lindahl, K ;
Ståhle, L ;
Söderberg, M ;
Schvarcz, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (08) :1573-1580
[4]   Dosage of ribavirin in patients with Hepatitis C should be based on renal function:: A population pharmacokinetic analysis [J].
Bruchfeld, A ;
Lindahl, K ;
Schvarcz, R ;
Ståhle, L .
THERAPEUTIC DRUG MONITORING, 2002, 24 (06) :701-708
[5]   Review article: renal function assessment in cirrhosis - difficulties and alternative measurements [J].
Cholongitas, E. ;
Shusang, V. ;
Marelli, L. ;
Nair, D. ;
Thomas, M. ;
Patch, D. ;
Burns, A. ;
Sweny, P. ;
Burroughs, A. K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (07) :969-978
[6]   Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].
De Franceschi, L ;
Fattovich, G ;
Turrini, F ;
Ayi, K ;
Brugnara, C ;
Manzato, F ;
Noventa, F ;
Stanzial, AM ;
Solero, P ;
Corrocher, R .
HEPATOLOGY, 2000, 31 (04) :997-1004
[7]  
Flamm SL, 2006, HEPATOLOGY, V44, p315A
[8]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[9]   Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy [J].
Guadagnino, V ;
Stroffolini, T ;
Rapicetta, M ;
Costantino, A ;
Kondili, LA ;
MennitiIppolito, F ;
Caroleo, B ;
Costa, C ;
Griffo, G ;
Loiacono, L ;
Pisani, V ;
Foca, A ;
Piazza, M .
HEPATOLOGY, 1997, 26 (04) :1006-1011
[10]   Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].
Hadziyannis, SJ ;
Sette, H ;
Morgan, TR ;
Balan, V ;
Diago, M ;
Marcellin, P ;
Ramadori, G ;
Bodenheimer, H ;
Bernstein, D ;
Rizzetto, M ;
Zeuzem, S ;
Pockros, PJ ;
Lin, A ;
Ackrill, AM .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355